Skip to main content

Table 3 Enrollment and outcomes in studies using Pritchard or modified Pritchard regimens

From: An integrative review of the side effects related to the use of magnesium sulfate for pre-eclampsia and eclampsia management

 

Enrollment N

Outcomes N (%)

Study

Subjects

Pre-eclampsia

Eclampsia

Affected patella reflex

Respiratory depression

Oliguria

Skipped dose

Calcium gluconate

Maternal death

All

Due to MgSO4

PRITCHARD

Alauddin

459

0

459

2

0

4

6

0

17

0

Bhattacharya

50

50

0

 

2

8

10

 

0

0

Bhattacharjee

70

0

70

  

0

  

3

0

Chowdhury

480

0

480

15

0

15

15

 

24

0

Chissell

9

9

 

0

0

0

0

 

0

0

Crowther

24

0

24

 

0

3

  

1

0

Ekele

19

0

19

0

0

1

1

0

0

0

Malapaka

54

16

38

19

1

19

331

 

1

1

Manorot

25

25

0

0

0

0

0

0

0

0

Mundle

153

153

0

   

122

 

0

0

Shoaib

50

50

  

0

   

0

0

SUBTOTALS

1393

303

1090

36 (2.6)

3 (0.2)

50 (3.6)

77 (5.5)

0 (0)

46 (3.3)

1 (0.1)

PRITCHARD MODIFIED

Bhattacharjee

67

 

67

0

0

0

0

 

1

0

Bhalla

45

0

45

 

0

2

 

0

0

0

Malapaka

72

37

35

5

0

7

125

 

1

0

Mahajan A 3

58

0

58

18

0

0

18

0

0

 

Mahajan B 4

37

0

37

21

0

3

24

0

0

 

Shoaib

50

50

  

0

   

0

0

SUBTOTALS

329

87

242

44 (13.4)

0 (0)

12 (3.7)

54 (16.4)

0 (0)

2 (0.6)

0 (0)

TOTALS

1722

390

1332

80 (4.7)

3 (0.2)

62 (3.6)

131 (7.6)

0 (0)

48 (2.8)

1 (0.1)

  1. 1 14 stopped due to signs of magnesium sulfate toxicity; 2 10 stopped treatment due to woman’s request, side effects, oliguria or renal failure, or signs of toxicity and 2 due to provider error or provider preference (Personal communication); 3Group A received 10 g loading dose; 4Group B received 6 g loading dose; 5 1 stopped due to signs of magnesium sulfate toxicity.
Back to article page

BMC Pregnancy and Childbirth

ISSN: 1471-2393

Contact us